In vivo studies show that miR-211 downregulation of Ssrp1 can mitigate RA symptoms by reducing pathological cell growth and inflammation as well as temporomandibular joint osteoarthritis [59,63]. Here, SSRP1 is linked to rheumatoid arthritis.